Sight Sciences, Inc. (NASDAQ:SGHT) Given Average Recommendation of “Hold” by Brokerages

Shares of Sight Sciences, Inc. (NASDAQ:SGHT) have received an average recommendation of “Hold” from the seven analysts that are currently covering the stock, Marketbeat reports. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $4.68.

A number of research analysts have weighed in on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of Sight Sciences in a research report on Tuesday, January 14th. Citigroup reduced their price target on shares of Sight Sciences from $5.80 to $4.60 and set a “neutral” rating on the stock in a research report on Wednesday, December 11th. Morgan Stanley reduced their price target on shares of Sight Sciences from $7.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Monday, November 11th. Piper Sandler reaffirmed a “neutral” rating and set a $5.50 price target (down from $6.00) on shares of Sight Sciences in a research report on Friday, November 8th. Finally, Stifel Nicolaus reduced their price target on shares of Sight Sciences from $6.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, February 6th.

Insider Transactions at Sight Sciences

In related news, CEO Paul Badawi sold 12,236 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $3.60, for a total value of $44,049.60. Following the sale, the chief executive officer now directly owns 5,713,197 shares of the company’s stock, valued at $20,567,509.20. This represents a 0.21 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last three months, insiders have bought 13,000 shares of company stock valued at $50,832 and have sold 63,014 shares valued at $197,295. Corporate insiders own 28.90% of the company’s stock.

Institutional Trading of Sight Sciences

Institutional investors have recently added to or reduced their stakes in the stock. KCK LTD. acquired a new stake in Sight Sciences in the fourth quarter valued at $15,925,000. Barclays PLC raised its holdings in Sight Sciences by 317.4% in the third quarter. Barclays PLC now owns 50,300 shares of the company’s stock valued at $317,000 after acquiring an additional 38,248 shares in the last quarter. Millrace Asset Group Inc. acquired a new stake in Sight Sciences in the third quarter valued at $874,000. Geode Capital Management LLC raised its holdings in Sight Sciences by 1.6% in the third quarter. Geode Capital Management LLC now owns 784,129 shares of the company’s stock valued at $4,941,000 after acquiring an additional 12,709 shares in the last quarter. Finally, State Street Corp increased its stake in Sight Sciences by 17.4% during the third quarter. State Street Corp now owns 646,776 shares of the company’s stock valued at $4,075,000 after purchasing an additional 95,843 shares during the last quarter. 55.51% of the stock is owned by institutional investors and hedge funds.

Sight Sciences Price Performance

Sight Sciences stock opened at $2.49 on Wednesday. Sight Sciences has a 1 year low of $2.29 and a 1 year high of $8.45. The firm has a 50 day moving average price of $3.06 and a 200 day moving average price of $4.58. The company has a market cap of $126.39 million, a price-to-earnings ratio of -2.44 and a beta of 2.52. The company has a debt-to-equity ratio of 0.36, a quick ratio of 9.74 and a current ratio of 10.18.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.